Loading...
XHKG1530
Market cap1.83bUSD
Dec 23, Last price  
6.03HKD
1D
-0.33%
1Q
2.73%
Jan 2017
-20.13%
IPO
-37.64%
Name

3SBio Inc

Chart & Performance

D1W1MN
XHKG:1530 chart
P/E
8.61
P/S
1.71
EPS
0.66
Div Yield, %
1.58%
Shrs. gr., 5y
-2.38%
Rev. gr., 5y
11.26%
Revenues
7.82b
+13.94%
00000000656,145,000875,396,0001,130,854,0001,673,126,0002,797,289,0003,734,334,0004,583,869,0005,318,091,0005,587,636,0006,382,009,0006,859,433,0007,815,938,000
Net income
1.55b
-19.13%
00000000101,666,00095,892,000291,728,000526,280,000712,564,000935,389,0001,277,167,000973,717,000835,791,0001,651,247,0001,915,727,0001,549,239,000
CFO
2.08b
-4.47%
144,449,000217,254,000386,589,000455,274,0001,004,324,0001,074,098,0001,150,251,0001,887,384,0001,344,561,0001,578,345,0002,180,278,0002,082,857,000
Dividend
Jul 22, 20240.25 HKD/sh
Earnings
Mar 18, 2025

Profile

3SBio Inc., an investment holding company, researches, develops, manufactures, markets, and sells biopharmaceutical products in the People's Republic of China. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; EPIAO and SEPO recombinant human erythropoietins to treat anemia; and Cipterbin for HER2-positive metastatic breast cancer in combination with chemotherapy. It also offers Mandi to treat male alopecia and alopecia areata; Xenopax for preventing acute rejection after renal transplant; Byetta for the glycemic control in patients with type 2 diabetes; Qiming Keli to treat retinopathy caused by type 2 diabetic; Aiyishu for iron-deficiency anemia; and SPARIN, an injectable low-molecular-weight heparin calcium for the treatment of prophylaxis and deep vein thrombosis, as well as for the prevention of clotting during hemodialysis. In addition, it offers Intefen, a recombinant human interferon to treat lymphatic or hematopoietic malignancies and viral infections; and Inleusin, a human interleukin2 for the treatment of renal cell carcinoma, melanoma, and thoracic fluid build-up. Further, the company provides trading, project management and consultation, technology, and agricultural services. It has collaboration agreements with companies, such as AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and Dana–Farber Cancer Institute. The company was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.
URL
https://www.3sbio.com/
IPO date
Jun 11, 2015
Employees
5,311
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
7,815,938
13.94%
6,859,433
7.48%
6,382,009
14.22%
Cost of revenue
5,456,142
4,845,216
4,555,663
Unusual Expense (Income)
NOPBT
2,359,796
2,014,217
1,826,346
NOPBT Margin
30.19%
29.36%
28.62%
Operating Taxes
392,167
366,016
241,193
Tax Rate
16.62%
18.17%
13.21%
NOPAT
1,967,629
1,648,201
1,585,153
Net income
1,549,239
-19.13%
1,915,727
16.02%
1,651,247
97.57%
Dividends
(224,883)
(417,140)
Dividend yield
1.22%
1.90%
Proceeds from repurchase of equity
337
(475,511)
(408,764)
BB yield
0.00%
2.16%
2.27%
Debt
Debt current
2,121,338
375,493
160,753
Long-term debt
2,754,053
4,132,891
2,511,070
Deferred revenue
416,914
396,627
Other long-term liabilities
667,313
4,474
5,568
Net debt
(946,746)
978,918
(1,452,706)
Cash flow
Cash from operating activities
2,082,857
2,180,278
1,578,345
CAPEX
(624,717)
(973,734)
(1,145,773)
Cash from investing activities
(1,345,355)
(3,721,985)
(1,286,516)
Cash from financing activities
(352,976)
714,912
(481,119)
FCF
6,117,889
(1,559,117)
(369,193)
Balance
Cash
5,992,081
7,010,514
4,703,285
Long term investments
(169,944)
(3,481,048)
(578,756)
Excess cash
5,431,340
3,186,494
3,805,429
Stockholders' equity
11,654,654
11,610,479
10,167,418
Invested Capital
16,587,416
16,946,940
13,734,359
ROIC
11.74%
10.74%
12.44%
ROCE
10.72%
9.87%
10.26%
EV
Common stock shares outstanding
2,441,666
2,648,209
2,770,119
Price
7.52
-9.40%
8.30
27.69%
6.50
-10.71%
Market cap
18,361,331
-16.46%
21,980,133
22.07%
18,005,773
-10.09%
EV
19,894,414
25,396,827
18,983,414
EBITDA
2,694,644
2,396,262
2,155,348
EV/EBITDA
7.38
10.60
8.81
Interest
212,296
101,053
66,525
Interest/NOPBT
9.00%
5.02%
3.64%